AGIO
Agios Pharmaceuticals, Inc.
34.00$
+2.7%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 73.1% | 80.3% | 90.4% | 72.5% | 71.5% | 68.7% | 74.6% | 74.0% | 67.2% | 89.0% | 58.1% | 72.6% | |
| 2.9% | 89.5% | 92.6% | 92.4% | 93.8% | 9.1% | 14.9% | 14.1% | 11.2% | 9.4% | 4.6% | 6.9% | |
| 69.5% | 89.5% | 92.6% | 92.4% | 93.8% | 63.4% | 67.2% | 70.9% | 63.2% | 82.9% | 53.7% | 65.9% | |
| 2.6% | 2.8% | 1.3% | 0.6% | 1.2% | 1.7% | 3.0% | 0.3% | 0.2% | 0.3% | 0.2% | 0.8% | |
| 0.0% | -14.0% | -5.2% | -23.4% | 0.1% | 0.8% | 1.7% | 1.1% | 0.7% | 2.0% | 1.7% | 2.5% | |
| 1.3% | 5.5% | 4.1% | 4.0% | 2.8% | 3.5% | 3.8% | 2.0% | 1.9% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 13.7% | 17.8% | 42.1% | 38.9% | 19.9% | 28.1% | 53.2% | 10.1% | 11.1% | 13.5% | 7.3% | 8.0% | |
| 12.4% | 12.6% | 14.3% | 15.5% | 10.9% | 10.4% | 11.1% | 4.2% | 5.1% | 7.3% | 4.9% | 6.3% | |
| 2.9% | 1.1% | 24.9% | 20.5% | 7.0% | 0.8% | 0.9% | 0.8% | 1.1% | 1.6% | 1.0% | 1.4% | |
| 2.2% | 3.5% | 2.8% | 3.7% | 2.1% | 2.5% | 2.1% | 1.2% | 1.5% | 1.0% | 1.0% | 1.4% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 86.3% | 82.2% | 57.9% | 61.1% | 80.1% | 71.9% | 46.8% | 89.9% | 88.9% | 86.5% | 92.7% | 92.0% | |
| -33.9% | -67.8% | -78.0% | -129.9% | -128.7% | -170.2% | -216.1% | -16.6% | -38.0% | -87.8% | -9.0% | -43.3% | |
| 6.8% | 8.9% | 6.3% | 7.6% | 6.7% | 6.7% | 8.1% | 4.2% | 4.4% | 5.9% | 3.5% | 4.5% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.